Biolab’s participation in the licensing of the influenza antiviral baloxavir marboxil illustrates how intellectual property, technical knowledge and industrial capacity can come together. The challenge is to turn that contractual framework into quality-assured production and effective access.
By Marcus Julius Zanon, 05/10/2026.
The value of a healthcare technology partnership becomes clear when the knowledge can be put to use, production meets quality requirements and the medicine reaches the people who need it. Between signing an agreement and achieving that outcome, however, lies a process that requires development, investment, regulatory decisions and institutional coordination.
The agreement between Roche and the Medicines Patent Pool (MPP) for baloxavir marboxil, an antiviral used to treat influenza, provides a concrete case for examining that process. Beyond announcing new manufacturers, the initiative invites discussion about what a licence contains, how technical knowledge is absorbed and how claims of industrial autonomy should be assessed.
For Brazil, the issue has immediate relevance: a Brazilian company is among the selected manufacturers.
Brazil joins an international manufacturing network
In a statement dated September 25, 2026, MPP announced sublicence agreements with eleven manufacturers across nine countries to develop and manufacture generic versions of baloxavir marboxil. They include Fidson in Nigeria and Biolab & Co. in Brazil. The selection follows the voluntary licence signed by Roche and MPP in May 2026 and brings together manufacturers with a global presence and others focused on regional markets.
Biolab stated that Biolab Farma will undertake product development and registration in Brazil. That announcement identifies an implementation stage; it does not establish that the generic product is already commercially available.
This distinction matters. Selection, development, regulatory approval, production and supply are separate stages. Progress at the first stage does not establish that the others have been completed.
A licence that includes technical knowledge
Under the published agreement, Roche grants MPP a non-exclusive licence to enter into sublicences within the agreed terms. The agreement provides for manufacturer selection and Roche’s approval, subject to contractual criteria. This structure allows different producers to access the licensed technology.
MPP’s official summary states that sublicensees may receive, upon request, a technical data package covering composition, manufacturing processes, specifications, methods, stability data, analytical method validation and impurities. Reference products for bioequivalence studies are also provided for.
These provisions are central to the analysis. Legal permission to use technology and the information needed to carry out a process address different needs. A sound assessment must examine both.
Yet the delivery of documents does not automatically mean that knowledge has been absorbed. The receiving organisation must be able to interpret the data, adapt its operations, reproduce results and solve problems within the scope of the technology received.
I therefore propose distinguishing three levels when assessing a partnership: legal access to the technology, delivery of the agreed knowledge and demonstrated ability to use it. Each requires its own evidence. A signed contract establishes a legal relationship; a technical report may document a deliverable; evidence from implementation is needed to demonstrate capability.
Territory and royalties: the economic boundaries of the licence
The expression “global licence,” used in news coverage, requires clarification. According to MPP, manufacturing is permitted worldwide, while the licensed territory comprises 129 countries, including Brazil. Supply outside that territory is possible where there are no patent barriers, subject to the applicable conditions.
Nor does the model provide for universal royalty-free access. The official summary specifies royalty-free supply for low-income countries and royalties of 5% of net sales for lower-middle-income countries and 10% for upper-middle-income countries. Payment obligations are linked to patent conditions, with exemptions where relevant granted and enforceable patents do not exist or would not be infringed by the activity.
These provisions show why the cost of a licence cannot be assessed solely by looking at a royalty rate. The destination market, contractual calculation basis, applicable rights and duration of the obligations must also be identified.
An investment decision must account for royalties alongside development, facilities, inputs, quality assurance, registration and distribution. Access to technology may improve the conditions for market entry, but sustainability depends on the operation as a whole.
Patent analysis remains necessary
The relationship between a licence and freedom to operate is often oversimplified.
As a matter of due diligence, the licence should be assessed against the product and manufacturing process that the company intends to implement. The questions are which rights the agreement actually covers and whether other relevant rights require examination.
No freedom-to-operate analysis for baloxavir in Brazil was conducted for this article. It would therefore be inappropriate to conclude that participation in the programme eliminates all patent risks involving third parties.
In a specific assessment, I would recommend mapping the relevant patent claims against manufacturing steps and product characteristics, while checking legal status, territory and contractual scope. This also helps distinguish an actual restriction from a patent reference that has no bearing on the intended activity.
The licence is an essential part of that assessment, but its scope must be established.
Emergency preparedness requires available capacity
MPP presents geographical diversification of manufacturing as part of preparedness for future health emergencies. The stated objective is to broaden supply options and strengthen regional production before a crisis creates urgency.
The agreement provides that, in the emergency or pandemic-risk circumstances it defines, Roche and MPP will assess needs and capacity and negotiate in good faith to address access barriers. These measures may concern supply constraints, territorial restrictions and royalties. This should not be confused with an automatic suspension of all restrictions.
The usefulness of that preparation will depend on factors that need to be monitored: availability of inputs, capacity to scale up production, regulatory progress and distribution arrangements.
In my view, a diverse manufacturing network creates valuable alternatives, but resilience must be assessed beyond factory location. A geographically dispersed network may remain vulnerable if its members depend on a single critical input or a concentrated supplier base.
What Brazilian institutions can learn
For companies, public laboratories and scientific and technological institutions, this case offers a reference for improving the assessment of proposed partnerships.
The first question should be: what capability does the institution intend to acquire? Developing a product, manufacturing an active ingredient, carrying out particular production stages, formulating, packaging and performing quality control are different objectives. The agreement must correspond to the intended outcome.
The next step is to define how that outcome will be demonstrated. Depending on the project, this may involve complete technical documentation, training, supervised execution, analytical results, demonstration batches and objective acceptance criteria. These are proposed assessment parameters, not a description of obligations specifically verified in Biolab’s sublicence.
Continuity also deserves attention. Which dependencies will remain? How will updates, improvements and confidential information be handled? What may continue to be used after the contractual relationship ends? These questions influence a partnership’s value from the outset.
For a public institution, technological interest must also be considered alongside institutional feasibility. An opportunity needs to fit its mission, investment capacity, demand and applicable procedures. The participation of other manufacturers in the agreement does not establish that another institution can join it.
Measuring results beyond the contract
The Roche–MPP agreement provides a relevant framework, but its effects on production, prices and access still need to be monitored. The sources reviewed do not establish that the initiative has already reduced prices in Brazil or delivered industrial autonomy.
That gap between design and results should guide project management. Useful indicators need to show knowledge actually absorbed, products developed, approvals obtained, available capacity and supply delivered.
Intellectual property can help organise cooperation and investment. For that contribution to reach public health, legal authorisation must be supported by technical execution, economic viability and institutional capacity.
The question this case poses for Brazil is concrete: when a technology partnership is completed, what will we be able to develop, manufacture and supply—and what evidence will demonstrate that capability?
This analysis is based on MPP’s announcement, its official licence summary, the published master agreement and Biolab’s statement, consulted on October 5, 2026. It does not include an implementation audit, a review of Biolab’s individual sublicence or a freedom-to-operate opinion.